Jeffrey Newcorn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1913587/publications.pdf

Version: 2024-02-01

23	1,217	14	20
papers	citations	h-index	g-index
25	25	25	1231
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Long-Term Treatment With Extended-Release Methylphenidate Treatment in Children Aged 4 to <6 Years. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, , .	0.3	8
2	A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). CNS Drugs, 2021, 35, 1035-1051.	2.7	16
3	Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 2019, 29, 432-443.	0.3	5
4	A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). CNS Drugs, 2018, 32, 289-301.	2.7	19
5	Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 602-609.e2.	0.3	21
6	Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs, 2017, 31, 999-1014.	2.7	33
7	Extendedâ€release guanfacine hydrochloride in 6–17â€year olds with ADHD: a randomisedâ€withdrawal maintenance of efficacy study. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 717-728.	3.1	26
8	Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. Addiction, 2015, 110, 784-795.	1.7	33
9	Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: A pilot fMRI study. Psychiatry Research - Neuroimaging, 2015, 231, 353-356.	0.9	9
10	Medication for ADHD and accidental injury. Lancet Psychiatry, the, 2015, 2, 669-671.	3.7	1
11	SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum. Scientific Reports, 2015, 5, 9257.	1.6	24
12	Recent Progress in Psychosocial and Psychopharmacologic Treatments for ADHD. Current Treatment Options in Psychiatry, 2015, 2, 14-27.	0.7	1
13	Comorbidity of ADHD and anxiety disorders. , 2014, , 98-110.		5
14	Randomized, Double-Blind Trial of Guanfacine Extended Release in Children With Attention-Deficit/Hyperactivity Disorder: Morning or Evening Administration. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 921-930.	0.3	49
15	Can Children With Callous and Unemotional Traits Be Treated Successfully?. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 1257-1259.	0.3	1
16	Dose–Response Characteristics in Adolescents with Attention-Deficit/Hyperactivity Disorder Treated with OROS [®] Methylphenidate in a 4-Week, Open-Label, Dose-Titration Study. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 187-196.	0.7	26
17	Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 511-518.	0.3	72
18	Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1165-1172.	0.3	35

#	Article	IF	CITATIONS
19	Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response. American Journal of Psychiatry, 2008, 165, 721-730.	4.0	294
20	Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder. Pediatrics, 2006, 118, e1701-e1706.	1.0	30
21	Atomoxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 240-248.	0.3	154
22	Symptom Profiles in Children With ADHD: Effects of Comorbidity and Gender. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 137-146.	0.3	347
23	New treatments and approaches for attention deficit hyperactivity disorder. Current Psychiatry Reports, 2001, 3, 87-91.	2.1	8